Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.

Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, et al.

J Nucl Med. 1992 Nov;33(11):1964-71.

2.

In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.

Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.

J Cereb Blood Flow Metab. 2001 Jan;21(1):92-7.

PMID:
11149673
3.

Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.

Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, et al.

Synapse. 1992 Mar;10(3):177-84.

PMID:
1532675
4.

Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.

Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK.

Neuroimage. 2005 Feb 1;24(3):822-31. Epub 2004 Nov 24.

PMID:
15652317
5.

Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.

Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.

J Nucl Med. 1996 Jan;37(1):11-5.

6.

Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.

Leslie WD, Abrams DN, Greenberg CR, Hobson D.

J Nucl Med. 1996 Oct;37(10):1589-91.

7.

Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.

Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H, Felix R.

Eur J Radiol. 1991 May-Jun;12(3):182-6.

PMID:
1830273
8.
9.

In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.

Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA.

Int J Rad Appl Instrum B. 1991;18(8):837-46.

PMID:
1839302
10.

Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans.

Varrone A, Fujita M, Verhoeff NP, Zoghbi SS, Baldwin RM, Rajeevan N, Charney DS, Seibyl JP, Innis RB.

J Nucl Med. 2000 Aug;41(8):1343-51.

11.

High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.

Kessler RM, Votaw JR, Schmidt DE, Ansari MS, Holdeman KP, de Paulis T, Clanton JA, Pfeffer R, Manning RG, Ebert MH.

Life Sci. 1993;53(3):241-50.

PMID:
8321085
12.

Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography.

Kuikka JT, Akerman KK, Hiltunen J, Bergström KA, Räsänen P, Vanninen E, Halldin C, Tiihonen J.

Eur J Nucl Med. 1997 May;24(5):483-7.

PMID:
9142727
13.

[In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].

Matsumura K, Toyama H, Nakashima H, Ichise M, Kurami M, Nakagawa T, Maeda H, Takeuchi A, Koga S.

Kaku Igaku. 1994 May;31(5):513-9. Japanese.

PMID:
8028224
14.

Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?

Verhoeff NP, Visser WH, Ferrari MD, Saxena PR, van Royen EA.

Cephalalgia. 1993 Oct;13(5):325-9.

PMID:
8242725
15.

Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.

Kessler RM, Votaw JR, de Paulis T, Bingham DR, Ansari MS, Mason NS, Holburn G, Schmidt DE, Votaw DB, Manning RG, et al.

Synapse. 1993 Nov;15(3):169-76.

PMID:
8278895
16.
17.

Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E.

J Neural Transm Gen Sect. 1995;99(1-3):187-93.

PMID:
8579804
18.

No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.

Vermeulen RJ, Drukarch B, Verhoeff NP, Goosen C, Sahadat MC, Wolters EC, van Royen EA, Stoof JC.

Synapse. 1994 Jun;17(2):115-24.

PMID:
7916490
19.

In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.

Kung HF, Alavi A, Chang W, Kung MP, Keyes JW Jr, Velchik MG, Billings J, Pan S, Noto R, Rausch, et al.

J Nucl Med. 1990 May;31(5):573-9.

20.

Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.

de Herder WW, Reijs AE, de Swart J, Kaandorp Y, Lamberts SW, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med. 1999 Jan;26(1):46-50.

PMID:
9933661

Supplemental Content

Support Center